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ABSTRACT
Cell surface receptors can undergo recycling or proteolysis but
the cellular decision-making events that sort between these pathways
remain poorly defined. Vascular endothelial growth factor A
(VEGF-A) and vascular endothelial growth factor receptor 2
(VEGFR2) regulate signal transduction and angiogenesis, but how
signaling and proteolysis is regulated is not well understood. Here, we
provide evidence that a pathway requiring the E1 ubiquitin-activating
enzyme UBA1 controls basal VEGFR2 levels, hence metering
plasma membrane receptor availability for the VEGF-A-regulated
endothelial cell response. VEGFR2 undergoes VEGF-A-
independent constitutive degradation via a UBA1-dependent
ubiquitin-linked pathway. Depletion of UBA1 increased VEGFR2
recycling from endosome-to-plasma membrane and decreased
proteolysis. Increased membrane receptor availability after UBA1
depletion elevated VEGF-A-stimulated activation of key signaling
enzymes such as PLCγ1 and ERK1/2. Although UBA1 depletion
caused an overall decrease in endothelial cell proliferation, surviving
cells showed greater VEGF-A-stimulated responses such as cell
migration and tubulogenesis. Our study now suggests that a ubiquitin-
linked pathway regulates the balance between receptor recycling
and degradation which in turn impacts on the intensity and duration of
VEGF-A-stimulated signal transduction and the endothelial
response.
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INTRODUCTION
Vascular endothelial growth factor A (VEGF-A) is an important
regulator of animal health and disease (Ferrara, 1999). VEGF-A-
stimulated pathological angiogenesis is an important player in chronic
inflammatory diseases, cancer and retinopathy (Carmeliet, 2005;
Coultas et al., 2005; Ferrara and Kerbel, 2005), whilst insufficient
angiogenesis leads to damaged blood vessels, causing tissue
ischaemia and heart disease (Ungvari et al., 2010). VEGF binding
to a vascular endothelial growth factor receptor (VEGFR) can trigger
multiple signal transduction pathways and cellular responses in
vascular and non-vascular cells and tissues. In particular, VEGF-A
binding to VEGFR2 on endothelial cells causes a diverse range of
pro-angiogenic responses (Olsson et al., 2006; Shibuya, 2010).
Although highly studied, it is not well understood how the endothelial
cell integrates multiple pathways to direct THE sprouting of new
blood vessels upon encountering ligands such as VEGF-A.
It is well-established that VEGF-A binding to plasma membrane
VEGFR2 causes tyrosine kinase activation and post-translational
modifications such as tyrosine trans-autophosphorylation and
ubiquitination (Ewan et al., 2006; Koch and Claesson-Welsh,
2012). Ligand-activated VEGFR2 can undergo ubiquitin-linked
proteolysis (Bruns et al., 2010; Ewan et al., 2006) which is regulated
by E3 ubiquitin ligases such as the proto-oncogene c-Cbl and β-
transducin repeat-containing protein (β-TrCP1) (Duval et al., 2003;
Shaik et al., 2012; Singh et al., 2007). However, it is unclear how the
endothelial cell regulates resting or basal VEGFR2 levels. One
possibility is that non-modified, basal VEGFR2 located at the
plasma membrane undergoes constitutive endocytosis and delivery
to lysosomes for proteolysis. An alternative explanation is that a
ubiquitination-dependent mechanism targets basal VEGFR2 for
trafficking to degradative compartments such as late endosomes and
lysosomes. A recent study has suggested that basal VEGFR2
turnover is regulated by an endosome-associated de-ubiquitinase,
USP8 (Smith et al., 2016). Furthermore, the E3 ubiquitin ligase
RNF121 controls turnover of newly synthesized VEGFR2 in the
secretory pathway (Maghsoudlou et al., 2016). Hence there is an
emerging body of evidence that ubiquitination of newly synthesized
or basal VEGFR2 trafficking and turnover.
Ubiquitination is a covalent modification involving the formation
of an isopeptide bond between the amino terminus of lysine side
chains with the free carboxyl terminus of ubiquitin monomers or
polymers. The addition of these ubiquitin moieties to a specific
protein can alter degradation, intracellular localization and modulate
protein activity. Adding such a modification first requires activity of
an E1 ubiquitin-activating enzyme, followed by an E2 ubiquitin-
conjugating enzyme working in concert with an E3 ubiquitin ligase
(Hershko and Ciechanover, 1992). Nine loci within the human
genome encode E1-related enzymes which initiate activation
and conjugation of a variety of ubiquitin and ubiquitin-like proteins
(e.g. SUMO, Nedd8) to target substrates (Pickart, 2001). This study
reveals the existence of a novel pathway that programs E1 ubiquitin
ligase-dependent modification of basal VEGFR2 to regulate
membrane trafficking and proteolysis. Such regulation is important
in controlling the endothelial response to VEGF-A by integrating
signal transduction, membrane trafficking and cellular responses.
RESULTS
UBA1 regulates basal VEGFR2 levels in endothelial cells
Ligand-stimulated ubiquitination of VEGFR2 facilitates trafficking
and degradation in the endosome-lysosome system (Bruns et al.,Received 28 June 2017; Accepted 4 August 2017
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2010). Previous work has shown that basal VEGFR2 also
undergoes proteolysis in primary endothelial cells (Mittar et al.,
2009; Ulyatt et al., 2011) but the underlying mechanism was
unknown. We hypothesized that ubiquitination of basal VEGFR2
targets this membrane receptor for trafficking and proteolysis. To
identify ubiquitin-linked regulators, we evaluated the requirement
for E1 ubiquitin-activating enzymes in controlling VEGFR2 levels
in human umbilical vein endothelial cells (HUVECs). Experiments
revealed that depletion of a major E1 enzyme, UBA1, caused a
significant 2.8-fold (P<0.01) increase in basal VEGFR2 levels
compared to controls (Fig. 1A,B). There was no significant effect
on basal levels of VEGFR1, another VEGFR family member
(Fig. 1A). Immunofluorescence microscopy analysis showed
increased staining for VEGFR2 but not VEGFR1 in UBA1-
depleted cells compared to controls (Fig. 1C). Quantification of
these staining patterns showed 2.8-fold (P<0.05) increase in
VEGFR2 levels upon UBA1 depletion (Fig. 1D). Treatment with
different UBA1-specific siRNA duplexes consistently increased
VEGFR2 levels, as observed using microscopy (Fig. S1A) and
quantification of morphological datasets (Fig. S1B). All UBA1-
specific siRNAs caused >80% decrease in UBA1 levels (Fig. S1C).
In contrast, VEGFR1 levels were not affected by UBA1 depletion
(Fig. 1E). As UBA1 and UBA6 are the only E1 ubiquitin-activating
enzymes that regulate ubiquitin attachment to target substrates
(Haas et al., 1982; Pelzer et al., 2007), we tested the effects of UBA6
depletion but found that this did not alter VEGFR2 or VEGFR1
levels (Fig. 1A-D). These data suggest that UBA1, but not UBA6,
regulates basal VEGFR2 levels.
The pharmacological inhibitor PYR41 irreversibly inhibits E1
enzyme activity whilst showing little or no activity against E2 or E3
enzymes (Yang et al., 2007). Immunoblot analysis of PYR41-
treated endothelial cells revealed an increase in basal VEGFR2
levels compared to untreated control (Fig. 1F). Quantification of
immunoblot data revealed a ∼30-40% increase in VEGFR2 levels
upon PYR41 treatment compared to control (Fig. 1G). Of note,
PYR41 effects on VEGFR2 levels were observed within 1 h of
treatment, whereas effects of RNAi-mediated depletion of UBA1
were observed 72 h after treatment. Taken together, both RNAi and
pharmacological studies suggest a role for UBA1 in regulating basal
VEGFR2 levels.
UBA1 regulates constitutive ubiquitination and degradation
of VEGFR2
Blocking new protein synthesis using cycloheximide (CHX)
enables the monitoring of mature VEGFR2 degradation (Shaik
et al., 2012). In these experiments, we combined CHX treatment and
RNAi-mediated UBA1 depletion to evaluate UBA1 contribution to
VEGFR2 turnover (Fig. 2). Immunoblotting confirmed that basal
VEGFR2 levels were elevated upon UBA1 depletion, in the absence
of VEGFR2 tyrosine phosphorylation (Fig. 2A). In comparing
VEGFR2 turnover to other membrane receptors, UBA1 depletion
did not affect basal levels of other cell surface receptors such as
fibroblast growth factor receptor 1 (FGFR1) or transferrin receptor
(TfR) (Fig. 2A). Quantification of relative protein levels upon CHX
treatment revealed that ∼60% of mature VEGFR2 underwent
constitutive degradation over an 80 min period (Fig. 2B). In
contrast, UBA1-depleted endothelial cells displayed a ∼40%
increase in basal VEGFR2 levels prior to CHX addition (t=0 min;
Fig. 2B). Upon subjecting UBA1-depleted cells to CHX treatment
for different time periods there was a gradual decrease in VEGFR2
levels, however these VEGFR2 levels were still higher (1.6-fold)
than in controls with normal UBA1 levels (Fig. 2B). Depletion of
UBA1 thus increases steady-state levels of mature VEGFR2 but this
is still subject to degradation with similar kinetics to controls
(Fig. 2B).
To further assess UBA1 involvement in controlling basal
VEGFR2 levels, we analyzed VEGFR2 distribution using
immunofluorescence microscopy (Fig. 2C). Quantification of
morphological datasets comparing control and UBA1-depleted
endothelial cells showed that basal VEGFR2 levels (t=0 min) were
∼60-70% higher in UBA1-depleted cells (Fig. 2D). Under control
conditions where new protein synthesis was blocked by CHX, cells
displayed a ∼55% decrease in overall VEGFR2 staining after
60 min, compared to the 0-min time point (Fig. 2D). In contrast,
CHX-treated and UBA1-depleted cells exhibited only a ∼20%
reduction in basal VEGFR2 levels over the same 60 min period
compared to the 0-min time point (Fig. 2D). A quantitatively similar
effect of UBA1 depletion on mature VEGFR2 was also seen in a
second vascular cell type, human dermal microvascular endothelial
cells (HDMECs) (Fig. S2A). Basal levels of mature VEGFR2 in
HDMECs were elevated by ∼20-30% after UBA1 depletion and
did not decrease significantly upon CHX treatment for up to 80 min
in comparison to controls (Fig. S2B). These data show UBA1
regulates basal VEGFR2 levels in different endothelial cells derived
from veins (HUVECs) and capillaries (HDMECs).
One likely explanation for UBA1-mediated regulation is that
basal VEGFR2 undergoes ubiquitination by a novel pathway. To
test this idea, mature VEGFR2 from control or UBA1-depleted
endothelial cells was immunoprecipitated and ubiquitination status
evaluated over a 0-80 min time course of CHX treatment (Fig. 2E).
At the 0-min time point, relative ubiquitination compared to total
VEGFR2 levels was not significantly different in UBA1-depleted
cells compared to controls (Fig. 2F). However, during the time
course of CHX treatment it was noticeable that ubiquitinated
VEGFR2 levels were significantly higher in control cells than in
UBA1-depleted cells (Fig. 2E). After 40 min of CHX treatment,
control cells exhibited 2.9-fold (P<0.01) greater levels of
ubiquitinated VEGFR2 compared to UBA1-depleted cells
(Fig. 2F). Thus reduction in UBA1 levels decreased basal
VEGFR2 ubiquitination.
UBA1 regulates basal VEGFR2 recycling
Ubiquitination at the plasma membrane frequently precedes
receptor tyrosine kinase (RTK) endocytosis, delivery to early
endosomes and further trafficking to lysosomes for terminal
degradation (Clague and Urbé, 2001; Ewan et al., 2006; Haglund
and Dikic, 2012). However, RTK de-ubiquitination in early or late
endosomes could also enable recycling from endosome-to-plasma
membrane (Clague and Urbé, 2006). Such features have previously
been observed in this system with VEGF-A-stimulated VEGFR2
ubiquitination promoting trafficking to late endosomes, linked to
terminal degradation in lysosomes (Bruns et al., 2010; Ewan et al.,
2006). Furthermore, VEGFR2 can also undergo substantial
constitutive ligand-independent recycling via endosomes (Jopling
et al., 2011). Another RTK such as FGFR1 undergoes similar
constitutive recycling (Hausott et al., 2012). One possibility is that
upon UBA1 depletion, VEGFR2 undergoes decreased basal
ubiquitination that in turn permits increased endosome-to-plasma
membrane recycling. To test this idea, we used a VEGFR2 recycling
assay (Jopling et al., 2011) in which control and UBA1-depleted
endothelial cells were incubated with antibodies specific for the
extracellular domains of VEGFR2 or FGFR1. Constitutive RTK
endocytosis and recycling was then monitored using accessibility of
VEGFR2-antibody and FGFR1-antibody complexes to a pulse of
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labeled secondary antibody. Only VEGFR2-antibody or FGFR1-
antibody complexes that underwent endocytosis followed by
endosome-to-plasma membrane recycling were detected in this
assay (Fig. 3A). Compared to control cells, UBA1-depleted
endothelial cells displayed a twofold (P<0.01) increase in
endosome-to-plasma membrane recycling of non-activated
VEGFR2 (Fig. 3B). In contrast, FGFR1 recycling was not
significantly affected by UBA1 depletion (Fig. 3C).
One possibility is that increased endosome-to-plasma membrane
recycling after UBA1 depletion caused an overall net increase in
plasma membrane VEGFR2 levels. To test this idea, new protein
synthesis was blocked with CHX and a cell surface biotinylation
assay was performed to monitor the plasma membrane pool.
Immunoblot analysis showed that basal VEGFR2 plasma
membrane levels in UBA1-depleted cells were ∼25% higher than
in control cells (t=0 min, Fig. 3D,E). Another cell surface receptor,
transferrin receptor, was not significantly affected (Fig. 3D). In
control cells treated with CHX, there was a ∼55% decrease in levels
of plasma membrane VEGFR2 (Fig. 3E). In contrast, under the
same CHX treatment of UBA1-depleted cells there was a less
marked (∼24%) decrease in plasma membrane VEGFR2 levels
(Fig. 3E). These data suggest that loss of UBA1 causes an increase
Fig. 1. UBA1 regulates basal VEGFR2 levels.
(A) Endothelial cells treated with non-targeting, UBA1 or
UBA6 siRNAwere lysed and immunoblotted with antibodies
to VEGFR2. (B) Quantification of VEGFR2 levels in non-
transfected cells and cells treated with control non-targeting
siRNA, UBA1 or UBA6 siRNA. (C) Immunofluorescence
analysis on endothelial cells which were either non-
transfected, treated with control non-targeting siRNA, UBA1
or UBA6 siRNA, fixed and stained with antibodies to
VEGFR1 or VEGFR2 followed by fluorescent species-
specific secondary antibodies (green). Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar: 70 μm.
Quantification of (D) VEGFR2 and (E) VEGFR1 levels
following immunofluorescence analysis of non-transfected
cells, cells treated with control non-targeting siRNA, UBA1
or UBA6 siRNA. (F) Non-treated endothelial cell control
lysates (−) compared to treatment (+) with 10 μMPYR41 for
1 h immunoblotted for VEGFR2, transferrin receptor (TfR)
and tubulin. (G) Quantification of VEGFR2 levels in
endothelial cell control versus PYR41 treatment. In panels
B, D, E and G, error bars denote mean±s.e.m. (n≥3), with
significance denoted as *P<0.05, **P<0.01, ***P<0.001;
analysed by one-way ANOVA.
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in plasma membrane VEGFR2 levels and is also consistent
with increased VEGFR2 recycling from endosome-to-plasma
membrane.
UBA1 regulates VEGFR2 trafficking to endosomes and
lysosomes
VEGFR2 undergoes endocytosis, delivery to endosomes and
recycling back to the plasma membrane or commitment for
terminal degradation in late endosomes and lysosomes (Ewan
et al., 2006; Jopling et al., 2014). If UBA1 depletion affects
VEGFR2 membrane dynamics, loss of UBA1 would be expected to
alter VEGFR2 distribution within these compartments. To ascertain
this, we compared VEGFR2 co-distribution with EEA1, CD63 or
LAMP2 (Fig. 4). UBA1-depleted endothelial cells exhibited a
∼50% increase in VEGFR2 co-distribution with the early endosome
marker EEA1 compared to controls (Fig. 4A,B). There was a
similar increase in VEGFR2 co-distribution with the late endosome
marker CD63 (Fig. 4B). In contrast, UBA1-depleted cells exhibited
Fig. 2. UBA1 regulates basal VEGFR2 degradation. (A) HUVECs transfected with non-targeting or UBA1 siRNA were treated with 20 µg/ml cycloheximide
(CHX) over a time course of 80 min and immunoblotted using antibodies to phospho-VEGFR2 (pY1175), VEGFR2, FGFR1 and TfR. (B) Quantification of
VEGFR2 levels in HUVECs transfected with non-targeting control siRNA or UBA1-specific siRNA combined with 20 µg/ml CHX treatment for 0-80 min
presented as decay curves. (C) HUVECs transfected with non-targeting control siRNA or UBA1-specific siRNAwere treatedwith 20 µg/ml CHX over a time course
of 0-60 min and visualized using immunofluorescence microscopy by staining with antibodies to VEGFR2 followed by fluorescent species-specific secondary
antibodies (green). Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar: 200 μm. (D) Quantification of VEGFR2 staining from the
immunofluorescence microscopy data shown in panel C presented as decay curves. (E) Primary human endothelial cells transfected with non-targeting control
siRNA or UBA1-specific siRNA were treated with 20 µg/ml CHX (0-80 min), lysed and VEGFR2 immuno-isolated and probed for ubiquitination status using a
ubiquitin-specific antibody. (F) Quantification of ubiquitinated VEGFR2 (Ub-VEGFR2) levels in endothelial cells from the isolation and immunoblotting
experiments shown in panel E. Relative Ub-VEGFR2 levels were normalized using total IgG and VEGFR2. IP, immunoprecipitate; WCL, whole cell lysate. In
panels B, D, E and F, error bars denote mean±s.e.m. (n≥3), with significance denoted as *P<0.05, **P<0.01, ***P<0.001; analysed by two-way ANOVA.
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a ∼34% decrease in VEGFR2 co-distribution with the lysosome
marker LAMP2 compared to control (Fig. 4B). These data suggest
that decreased UBA1 levels alter VEGFR2 distribution within the
endosome-lysosome network.
UBA1 regulates VEGF-A-stimulated signal transduction
VEGF-A binding to plasma membrane VEGFR2 stimulates
multiple signal transduction pathways (Koch et al., 2011; Zhang
et al., 2008). Our experiments now show that UBA1 depletion
leads to a net increase in plasma membrane VEGFR2; this could
modulate VEGF-A-stimulated signal transduction. To test this
idea, control and UBA1-depleted endothelial cells were stimulated
with VEGF-A before probing downstream signaling events using
quantitative immunoblotting (Fig. 5). VEGFR2 activation is
exemplified by phosphorylation on cytoplasmic residue Y1175
(Koch et al., 2011); this was clearly evident in both control and
UBA1-depleted cells (Fig. 5A). However, UBA1 depletion caused
a significant ∼30% increase in VEGFR2-pY1175 levels (Fig. 5B).
Plasma membrane VEGFR2 activation is also linked to
recruitment of phospholipase Cγ1 (PLCγ1) followed by tyrosine
phosphorylation on residue Y783 and increased phospholipase
activity (Koch et al., 2011). UBA1-depleted cells exhibited
enhanced PLCγ1 phosphorylation (Fig. 5A) with ∼43% increase
in PLCγ1-pY783 levels (Fig. 5C). A key feature of VEGF-A-
stimulated signaling is activation of the canonical mitogen-
activated protein kinase (MAPK) pathway leading to
phosphorylation and activation of extracellular signal-regulated
kinase enzymes 1 and 2 (ERK1/2) (Koch and Claesson-Welsh,
2012). VEGF-A stimulation caused a 3.7-fold (P<0.05) increase in
ERK1/2 phosphorylation in UBA1-depleted endothelial cells
compared to controls (Fig. 5A,D). UBA1-depleted cells contained
∼40% higher basal VEGFR2 levels. Surprisingly, the kinetics of
VEGF-A-stimulated VEGFR2 degradation were not significantly
affected by UBA1 depletion (Fig. 5A,E). Thus, UBA1 is not
required for VEGF-A-stimulated VEGFR2 degradation.
These data suggest that increased VEGFR2 phosphorylation in
UBA1-depleted cells (Fig. 5B) was due to an overall net increase in
plasma membrane VEGFR2 levels rather than effects on VEGFR2
activation at the individual receptor level (Fig. 5F). To test whether
UBA1 depletion affects other RTK signal transduction events,
UBA1-depleted endothelial cells were subjected to a time-course of
bFGF which is known to activate FGFR1-regulated MAPK signal
transduction in endothelial cells. Both control and UBA1-depleted
cells exhibited similar responses to bFGF stimulation such as
ERK1/2 activation (Fig. 5G). Thus UBA1 regulates signal
transduction by VEGFR2 but not FGFR1.
Basal VEGFR2 turnover regulates VEGF-A-dependent
endothelial cell tubulogenesis
UBA1 is the principal E1 enzyme in human cells and is likely to be
involved in many cellular processes (Groen and Gillingwater,
2015). Depletion of UBA1 caused 2.4-fold (P<0.001) decrease in
endothelial cell proliferation in the absence of VEGF-A (Fig. 6A).
However, remaining viable endothelial cells showed a 2.3-fold
increase in VEGF-A-stimulated proliferation compared to a 1.7-fold
increase in control cells (P<0.01) (Fig. 6B). Signal transduction
Fig. 3. UBA1 regulates basal ubiquitination, recycling and plasmamembrane levels of VEGFR2. (A) Endothelial cells transfected with non-targeting control
siRNA or UBA1-specific siRNA were incubated with antibodies to the extracellular domains of VEGFR2 or FGFR1 for 30 min at 37°C prior to acid-wash to strip
cell surface antibodies, and incubation with fluorescent species-specific secondary antibodies for 30 min at 37°C (green). Cells were fixed prior to staining with
DAPI (blue). Only VEGFR2 or FGFR1 that underwent plasma membrane-to-endosome-to-plasma membrane recycling is visible. Scale bar: 200 μm.
Quantification of (B) VEGFR2 and (C) FGFR1 recycling in endothelial cells transfected with non-targeting control siRNA or UBA1-specific siRNA. (D) Endothelial
cells transfected with non-targeting control siRNA or UBA1-specific siRNA were treated with 20 µg/ml CHX for 0-80 min before cell surface proteins were
biotinylated, isolated and immunoblotted for plasma membrane VEGFR2 (PM VEGFR2), transferrin receptor (TfR), UBA1 and tubulin. IP, immunoprecipitate;
WCL, whole cell lysate. (E) Quantification of immunoblot data shown in panel D with relative values for cell surface VEGFR2 levels denoted in the histogram. In
panels B and E, error bars denote mean±s.e.m. (n≥3), with significance denoted as *P<0.05, **P<0.01; analysed using one-way ANOVA (panel B) and two-way
ANOVA (panel E).
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by VEGF-A-activated VEGFR2 promotes new vascular tube
formation by endothelial cells, an essential feature in angiogenesis
(Ferrara, 1999). Immunoblotting confirmed that UBA1-specific
siRNA transfection was effective at depleting endothelial UBA1
levels for extended periods (Fig. 6C), corresponding to the 7-day
duration of the tubulogenesis assay. UBA1-depleted cells exhibited
lower tubule length (Fig. 6D) and number of tubule branch points
(Fig. 6E) in absolute numbers compared to non-transfected or
control siRNA-transfected controls. However, VEGF-A stimulation
of UBA1-depleted cells increased tubule length 4.4-fold (Fig. 6F)
and branch point number 22.3-fold when compared to
UBA1-depleted cells in the absence of VEGF-A (Fig. 6F). These
effects were substantially higher than the VEGF-A-stimulated 2.6-
fold (P<0.01) increase in tubule length (Fig. 6F) and 4.6-fold
(P<0.001) increase in branch point number (Fig. 6G) for
control siRNA-transfected controls. These findings show that
UBA1 has functional impact on VEGF-A-stimulated endothelial
tubulogenesis.
VEGF-A-stimulated endothelial cell migration is elevated by
decreased UBA1 levels
VEGF-A-dependent signaling also stimulates endothelial cell migration
(Fearnley et al., 2014; Smith et al., 2015a,b). To test the role of UBA1,
we analyzed control and UBA1-depleted endothelial cells for migration
towardsVEGF-A (Fig. 7A). Quantification of these images showed that
UBA1 depletion caused an overall decrease in non-stimulated and
VEGF-A-stimulated endothelial cell migration compared to non-
transfected or control siRNA-transfected cells (Fig. 7B). However,
comparison of non-stimulated versus VEGF-A-stimulated migration of
UBA1-depleted cells showed 14.6-fold increase in VEGF-A-stimulated
endothelial cell migration (Fig. 7C). This effect was 3.7-fold (P<0.001)
higher than the VEGF-A-stimulated migration exhibited by control
siRNA-transfected cells (Fig. 7C). We also tested the VEGF-A-
stimulated closure of a wounded endothelial cell monolayer which
represents both cell proliferation and migration. There was a significant
VEGF-A-stimulated re-occupation of the wounded area by
UBA1-depleted cells in comparison to non-transfected and control
Fig. 4. UBA1 depletion perturbs VEGFR2 endosome-lysosome dynamics. (A) Endothelial cells transfected with non-targeting or UBA1 siRNA were
processed for immunofluorescence microscopy using antibodies to VEGFR2 (green), EEA1 (red), CD63 (red) or LAMP2 (red) followed by fluorescent species-
specific secondary antibodies. Nuclei were stained with DNA-binding dye, DAPI (blue). Scale bar: 70 μm. (B) Quantification of VEGFR2 co-distribution with
early endosome (EEA1), late endosome (CD63) and lysosome (LAMP2) markers in endothelial cells transfected with non-targeting control siRNA or
UBA1-specific siRNA. Error bars denote mean±s.e.m. (n≥3), with significance denoted as *P<0.05; analysed using two-way ANOVA.
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siRNA-treated cells (Fig. 7D). This experiment showed a ∼31%
increase in VEGF-A-stimulated wound closure in UBA1-depleted cells
compared to control siRNA-treated cells (Fig. 7E). These data show that
loss of UBA1 elevates the endothelial cell response to VEGF-Awhich
is reflected reflected by endothelial endothelial cell migration and
monolayer wound closure.
Fig. 5. UBA1 depletion causes an increase in VEGF-A-stimulated signal transduction. (A) Endothelial cells transfected with non-targeting control siRNA or
UBA1-specific siRNA were stimulated with 25 ng/ml VEGF-A for specific time periods (0-60 min), lysed and immunoblotted for phospho-VEGFR2 (Y1175),
phospho-PLCγ1 (Y783), phospho-ERK1/2 (T202/Y204), VEGFR2, ERK1/2, UBA1 and tubulin. Quantification of (B) phospho-VEGFR2, (C) phospho-PLCγ1,
(D) phospho-ERK1/2, and (E) VEGFR2 levels in endothelial cells transfected with non-targeting control siRNA or UBA1-specific siRNA and treated with 25 ng/ml
VEGF-A for the time periods indicated. Relative levels for each signal were normalized against tubulin. (F) Quantification of phospho-VEGFR2 (Y1175) levels after
5 min VEGF-A stimulation and normalized against total VEGFR2 levels in control or UBA1-depleted endothelial cells. (G) Endothelial cells transfected with non-
targeting control siRNA or UBA1-specific siRNA were treated with 25 ng/ml basic FGF (bFGF), lysed and immunoblotted for phospho-ERK1/2 (T202/Y204),
VEGFR2, FGFR1, UBA1 and tubulin. In panels B-F, error bars denote mean±s.e.m. (n≥3), with significance denoted as *P<0.05, ***P<0.001; analysed using
two-way ANOVA.
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DISCUSSION
Our study now provides compelling evidence for a ubiquitin-linked
pathway which regulates basal VEGFR2 levels and impacts on
VEGF-A-stimulated signal transduction and multiple cellular
responses. Our findings support the existence of a mechanism
whereby cells adjust the net pool of plasma membrane VEGFR2,
Fig. 6. UBA1 influences VEGF-A-stimulated endothelial cell proliferation and tubulogenesis. (A) Endothelial cells transfected with non-targeting control
siRNAor UBA1-specific siRNAwere analyzed for cell proliferation using a bromodeoxyuridine (BrdU) incorporation assay. (B) Quantification of VEGF-A-stimulated
cell proliferation, expressed as fold increase over the corresponding values for non-stimulated cells. (C) Endothelial cells transfected with non-targeting control
siRNA or UBA1-specific siRNA for 3 or 7 days were lysed and UBA1 levels assessed by immunoblotting. Quantification of VEGF-A-stimulated endothelial
tubulogenesis (seeMaterials andMethods) byevaluating (D) total tubule lengthand (E) total numberof branchpoints relative to the non-transfected, non-stimulated
(-VEGF-A) condition. Quantification of VEGF-A-stimulated endothelial tubulogenesis by evaluating (F) total tubule length, and (G) total number of branch points
expressed as fold increase over corresponding values for non-stimulated cells in non-transfected, control siRNA-treated or UBA1-treated cells. In panels A, B and
D-G, error bars denote mean±s.e.m. (n≥3), with significance denoted as *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; analysed using two-way ANOVA.
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thus controlling RTK-mediated signal transduction and the cellular
response to extracellular ligands such as VEGF-A. This ligand-
independent regulatory pathway mediates VEGFR2 availability at
the plasma membrane for VEGF-A-stimulated signal transduction.
The E1 enzyme, UBA1, regulates basal plasma membrane VEGFR2
levels which influence VEGF-A-stimulated activation of PLCγ1 and
ERK1/2 signal transduction pathways. A key point is that UBA1
influences the pool of plasma membrane VEGFR2 which in turn
dictates net VEGFR2 activation.
VEGFR2 ubiquitination plays key roles in membrane trafficking
and degradation but previous work has focused on VEGF-stimulated
responses (Bruns et al., 2010; Ewan et al., 2006; Smith et al., 2015a,b).
Our study now highlights a mechanism involving UBA1 which
controls basal VEGFR2 levels and VEGF-A-stimulated cellular
Fig. 7. UBA1 influence on VEGF-A-stimulated endothelial cell migration and monolayer wound closure. (A) Non-transfected endothelial cells or cells
transfected with non-targeting control siRNA or UBA1-specific siRNA were seeded into Transwell filters and stimulated with VEGF-A (25 ng/ml) for 24 h, then
fixed and stained. Scale bar: 1000 μm. (B) Quantification of endothelial cell migration relative to the non-transfected, non-stimulated (-VEGF-A) condition.
(C) Quantification of the VEGF-A-dependent increase in cell migration expressed as fold increase over the corresponding values for non-stimulated cells.
(D) Endothelial cell monolayers transfected with non-targeting control siRNA or UBA1-specific siRNAwerewounded (0 h), treated with 25 ng/ml VEGF-A for 24 h and
images recorded bymicroscopy. (E)Quantification of VEGF-A-stimulated endothelialmonolayerwound closure in cells transfectedwith non-targeting control siRNAor
UBA1-specific siRNA. In panels B, C and E, error bars denotemean±s.e.m. (n≥3), with significance denoted as *P<0.05, **P<0.01; analysed using two-way ANOVA.
1412
RESEARCH ARTICLE Biology Open (2017) 6, 1404-1415 doi:10.1242/bio.027896
B
io
lo
g
y
O
p
en
 by guest on January 26, 2018http://bio.biologists.org/Downloaded from 
responses. This type of RTK ubiquitination is closely linked to
trafficking as highlighted by perturbation of VEGFR2 endosome-to-
plasma membrane recycling when UBA1 levels are depleted. Under
these conditions, VEGFR2 showed increased co-distribution with
endosomes but reduced co-distributionwith lysosomes. Trafficking of
other plasma membrane receptors such as transferrin receptor
and another RTK (FGFR1) did not show UBA1-dependence,
suggesting this UBA1-regulated pathway has specificity for a
subset of proteins which includes VEGFR2. Nonetheless, such
ubiquitin-linked regulation of basal VEGFR2 has important
consequences for VEGF-A-stimulated cellular responses such as
endothelial tubulogenesis, migration and proliferation: there is
clear elevation in VEGF-A-stimulated pro-angiogenic responses
upon UBA1 depletion.
Ligand-stimulated ubiquitination of VEGFR2 programs
terminal degradation in lysosomes (Ewan et al., 2006).
Conflicting studies implicate E3 ligases Cbl proto-oncogene E3
ubiquitin protein ligase (c-Cbl) and β-transducin repeat containing
E3 ubiquitin protein ligase (β-TrCP1) in VEGF-A-stimulated
proteolysis of VEGFR2 (Bruns et al., 2010; Duval et al., 2003;
Murdaca et al., 2004; Shaik et al., 2012; Singh et al., 2007).
Furthermore, differences in VEGFR1 and VEGFR2 proteolysis
under either resting (Mittar et al., 2009) or hypoxic (Ulyatt et al.,
2011) conditions suggest that endothelial cells exploit VEGFR
availability to fine-tune the cellular response to VEGF-A. Recent
studies have also highlighted ligand-independent VEGFR2 de-
ubiquitination linked to the de-ubiquitinase USP8 that controls
membrane trafficking, recycling and proteolysis (Smith et al.,
2015a,b). Interestingly, kinase-independent regulation of RTK
function is highlighted by the discovery that constitutive binding
of cytosolic adaptors such as growth factor receptor-binding
protein 2 (Grb2) to basal FGFR2 regulates ligand-independent
activation of downstream signaling pathways (Lin et al., 2012). In
addition, ligand-independent ubiquitination and endocytosis of
EGFR involves the Hrs endocytic adaptor protein (Katz et al.,
2002) that is found on a subset of early endosomes. There is also a
new kinase-independent autophagic role for EGFR (Tan et al.,
2015). These diverse studies emphasize how ligand-independent
control of RTK turnover and function can impact on ligand-
stimulated cellular responses.
UBA1 is an essential cellular enzyme expressed by many cells
and tissues and is functionally implicated in multiple pathways
including DNA replication. Notably, suppression of UBA1 activity
in Schwann cells is linked to spinal muscular atrophy (Aghamaleky
Sarvestany et al., 2014; Sugaya et al., 2015). Other studies have
identified UBA1 as a novel target for the treatment of hematological
malignancies (Xu et al., 2010; Yang et al., 2007). UBA1-mediated
surveillance of disease-linked responses could thus be utilized for
controlling RTK levels and cellular responses in different tissues.
The potential for UBA1 in cell proliferation and disease is
highlighted in the profiling of certain cancers (e.g. prostate
cancer) which show reduced UBA1 expression (www.
proteinatlas.org). One mechanism employed by cancerous cells
could be down-regulation of UBA1 expression to stimulate tumor
angiogenesis. By providing a UBA1-regulated mechanism to
control basal VEGFR2 availability which impacts on signal
transduction and cellular responses, our study provides a non-
canonical pathway that is unique to the established model for
ligand-stimulated RTK ubiquitination, trafficking and proteolysis.
Our findings provide a new understanding of ubiquitin-linked
regulation of VEGF-regulated outcomes and could be of use to new
strategies that target angiogenesis in diverse disease states.
MATERIALS AND METHODS
Cell culture and materials
Primary HUVECs were cultured as previously described (Fearnley et al.,
2014; Howell et al., 2004), HDMECs and appropriate growth media were
from PromoCell (Heidelberg, Germany). Purified primary and secondary
antibodies were typically used at 1 µg/ml for microscopy and at 0.1 µg/ml
for immunoblotting. These antibodies were goat anti-VEGFR2 (R&D
Systems, Minneapolis, USA), rabbit anti-phospho-VEGFR2 (Y1175),
rabbit anti-UBA1 (Cell Signaling Technologies, Danvers, USA), rabbit
antibodies to native and phosphorylated PLCγ1 (Y783), rabbit anti-ERK1/
2, mouse anti-phospho-ERK1/2 (T202, Y204), mouse anti-α-tubulin (Santa
Cruz Biotechnology, USA), mouse anti-transferrin receptor (TfR), mouse
FK2 anti-ubiquitin (Affiniti Research Products, Exeter, UK), mouse
anti-EEA1 (BD Biosciences, California, USA), mouse anti-CD63
(Abcam, Cambridge, UK), mouse anti-LAMP2 (Santa Cruz, USA),
HRP-conjugated secondary antibodies (Thermo Fisher, Loughborough,
UK) and Alexa Fluor-conjugated secondary antibodies (ThermoFisher).
Endothelial cell growth medium (PromoCell), non-targeting and UBA1
siRNA duplexes (GE Dharmacon, UK) and recombinant human VEGF-
A165 (Genentech Inc., San Francisco, USA) were obtained as stated.
Chemicals were obtained from Sigma-Aldrich (Poole, UK) or Thermo
Fisher (Loughborough, UK).
Immunoblotting and immunofluorescence microscopy
Endothelial cells were serum starved in MCDB131 (Thermo Fisher) for 2 h
prior to treatment with 25 ng/ml VEGF-A165 (0-60 min), 20 μg/ml CHX
(0-80 min) or 10 μM PYR41 (1 h) and lysed for immunoblotting or
immunoprecipitation studies. Cells were lysed in 2% (w/v) SDS and run on a
10% SDS-PAGE gel at 120 V for 90 min. Proteins were transferred onto
nitrocellulose membrane at 300 mA for 3 h and incubated in primary
antibodies overnight prior to incubation in HRP-conjugated secondary
antibodies for 1 h and detection using enhanced chemiluminescence.
Immunoblots were quantified, normalized against tubulin and made
relative to the control (i.e. the control siRNA 0 min condition) for
representation on graphs. For immunofluorescence analysis, HUVECs
were seeded in 96-well plates or on cover-slips before fixation,
permeabilization in 0.1% (w/v) Triton X-100, incubation with primary
antibodies and visualization by incubation in Alexa Fluor488- or 594-
conjugated secondary antibodies and DAPI. Images were acquired using
an EVOS-fl inverted digital microscope (Thermo Fisher) at 20×
magnification or a wide-field deconvolution microscope DeltaVision
(Applied Precision Inc., Issaquah, USA) at 60× magnification at room
temperature. Fluorescence intensity (integrated density) and co-
localization (co-localization threshold plugin) were quantified using
NIH ImageJ (https://imagej.nih.gov/ij/download.html).
Immunoprecipitation analysis
HUVECs were serum starved for 2 h prior to CHX treatment or VEGF-A
stimulation, lysed in buffer [150 mMNaCl, 50 mM Tris-HCl, pH 7.4, 0.1%
(w/v) SDS, 0.5% (w/v) sodium deoxycholate, 2 mM EDTA, 1% (v/v) NP-
40, 50 mM NaF, 1 mM PMSF, 10 mM iodoacetamide], incubated with
1 μg/ml goat anti-VEGFR2 for 2 h and immuno-isolated with protein
G-agarose beads before SDS-PAGE and immunoblot analysis.
Plasma membrane protein recycling assay
HUVECs were incubated in primary antibody to VEGFR2 or FGFR1 for
30 min at 37°C. Cell surface-bound primary antibody was stripped by
washing in acidic MCDB131 medium (pH 2.0) at 4°C. Cells were incubated
in secondary antibody (anti-sheep Alexa Fluor488) for 30 min at 37°C and
fixed for 5 min at 37°C before incubation with 1 μg/ml DAPI to visualize
nuclear DNA. Only cell surface VEGFR2 that had bound primary antibody
and undergone internalization and subsequent recycling would be available
to bind secondary antibody after acid-washing. Thus, only VEGFR2 that
recycled one or more times was visualized. Images were acquired using an
EVOS-fl inverted digital microscope at 20× magnification at room
temperature. Fluorescence intensity was quantified using NIH ImageJ
(https://imagej.nih.gov/ij/download.html).
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Cell surface biotinylation
HUVECs were serum starved for 2 h prior to CHX treatment, washed in ice-
cold PBS, cell surface biotinylated by incubation with 0.25 mg/ml biotin in
buffer (2 mM CaCl2, 2 mM MgCl2, PBS) for 45 min, washed in TBS to
quench biotinylation and lysed in NP-40 lysis buffer [1% (v/v) NP-40,
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM PMSF]. Cell surface
proteins were isolated using NeutraAvidin agarose beads before SDS-PAGE
and immunoblotting.
Protein depletion using RNAi
Endothelial cells were reverse transfected in 6- or 96-well plates with 4 pooled
siRNA duplexes (SMARTpool siRNA, GE Dharmacon) as follows. 20 nM
non-targeting control siRNA: 5′-UGGUUUACAUGUCGACUAA-3′; 5′-
UGGUUUACAUGUUGUGUGA-3′; 5′-UGGUUUACAUGUUUUCUGA-
3′; 5′-UGGUUUACAUGUUUUCCUA-3′. 20 nM UBA1 siRNA: 5′-GCG-
UGGAGAUCGCUAAGAA-3′; 5′-CCUUAUACCUUUAGCAUCU-3′; 5′-
CCACAUAUCCGGGUGACAA-3′; 5′-GAAGUCAAAUCUGAAUCGA-3′.
All siRNA duplexes were used according to the manufacturer’s
instructions (GE Dharmacon). Endothelial cells were incubated for 6 h
with siRNA duplexes using a previously described lipid-based transfection
protocol (Fearnley et al., 2014). After 72 h, cells were processed for lysis
and immunoblotting as previously described.
Cell migration and proliferation assays
For the cell migration assay, 48 h after transfection with control or UBA1
siRNA, HUVECs were seeded in starvation media (MCDB131) at 3×104
cells per well in an 8 μm pore size Transwell filter inserted into a 24-well
companion plate (BD Biosciences, Oxford, UK). MCDB131 containing
25 ng/ml VEGF-Awas added to the lower chambers to set up a chemotactic
gradient for cells to migrate towards. Cells were incubated for 24 h before
being fixed and stained with 0.2% (w/v) crystal violet in 20% (v/v)
methanol. Non-migrated cells were removed from the upper chamber. 3-5
random fields were imaged per Transwell filter.
For the cell proliferation assay, 48 h after transfection with control or
UBA1 siRNA, HUVECs were seeded at 2×103 cells per well in 96-well
plates in complete growth media. After 24 h cells were serum starved in
MCDB131 for 2 h prior to stimulation with 25 ng/ml VEGF-A for 24 h. At
the 20 h time point, 10 μMbromodeoxyuridine (BrdU) was added and a cell
proliferation ELISA performed according to manufacturer’s instructions
(Roche Diagnostics, Burgess Hill, UK). Color change was developed using
3,3′5,5′-tetramethylbenzidine solution and the reaction quenched with 1 M
H2SO4. Absorbance was measured at 450 nm using a variable wavelength
96-well Tecan Sunrise plate reader (Mannedorf, Switzerland).
Endothelial tubulogenesis and monolayer wound assays
For the tubulogenesis assay, HUVECs transfected with siRNAwere seeded
onto a bed of confluent primary human fibroblasts and stimulated with
25 ng/ml VEGF-A every 48 h for 7 days. Co-cultures were grown in 50:50
ECGM and DMEM [with 10% (v/v) FCS, 1% sodium pyruvate, 1% non-
essential amino acids]. Tubules were stained with endothelial-specific
marker, PECAM-1, overnight and incubated in anti-mouse secondary
antibody (Alexa Fluor 594) and DNA-binding dye, DAPI, for 2 h at room
temperature. Images were acquired using an Evos-fI inverted digital
microscope. Five random fields were imaged per well at 10× magnification
at room temperature. Both total tubule length and the number of branch points
were quantified from each photographic field using the open source software
AngioQuant (www.cs.tut.fi/sgn/csb/angioquant) and values averaged.
For the monolayer wound assay, endothelial cells were transfected with
control or UBA1 siRNA and grown to a confluent monolayer in ECGM for
48 h. The cell monolayer was scratched using a 1 ml blue plastic pipette tip
at the 0 h time point and stimulated with 25 ng/ml VEGF-A. After 24 h,
wound closure was captured using an Evos-fI inverted digital microscope
and scratch width quantified using ImageJ.
Statistical analysis
This was performed using a one-way analysis of variance (ANOVA) and
Tukey’s post-test analysis for multiple comparisons or two-way ANOVA
followed by the Bonferroni multiple comparison test using GraphPad
Prism software (La Jolla, USA). Significant differences between control
and test groups were evaluated with *P<0.05, **P<0.01, ***P<0.001 and
****P<0.0001 indicated on the graphs. Error bars in graphs denote
mean±s.e.m. of results from at least three independent experiments.
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Clague, M. J. and Urbé, S. (2001). The interface of receptor trafficking and
signalling. J. Cell Sci. 114, 3075-3081.
Clague, M. J. and Urbé, S. (2006). Endocytosis: the DUB version. Trends Cell Biol.
16, 551-559.
Coultas, L., Chawengsaksophak, K. and Rossant, J. (2005). Endothelial cells
and VEGF in vascular development. Nature 438, 937-945.
Duval, M., Bédard-Goulet, S., Delisle, C. and Gratton, J.-P. (2003). Vascular
endothelial growth factor-dependent down-regulation of Flk-1/KDR involves cbl-
mediated ubiquitination-consequences on nitric oxide production from endothelial
cells. J. Biol. Chem. 278, 20091-20097.
Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J.,
Walker, J. H., Zachary, I. C. and Ponnambalam, S. (2006). Intrinsic tyrosine
kinase activity is required for vascular endothelial growth factor receptor 2
ubiquitination, sorting and degradation in endothelial cells. Traffic 7, 1270-1282.
Fearnley, G. W., Smith, G. A., Odell, A. F., Latham, A. M., Wheatcroft, S. B.,
Harrison, M. A., Tomlinson, D. C. and Ponnambalam, S. (2014). Vascular
endothelial growth factor A-stimulated signaling from endosomes in primary
endothelial cells Meth. Enzymology 535, 265-292.
Ferrara, N. (1999). Role of vascular endothelial growth factor in the regulation of
angiogenesis. Kidney Int. 56, 794-814.
Ferrara, N. and Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature
438, 967-974.
Groen, E. J. N. and Gillingwater, T. H. (2015). UBA1: at the crossroads of ubiquitin
homeostasis and neurodegeneration. Trends Mol. Med. 21, 622-632.
Haas, A. L., Warms, J. V., Hershko, A. and Rose, I. A. (1982). Ubiquitin-activating
enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257,
2543-2548.
Haglund, K. and Dikic, I. (2012). The role of ubiquitylation in receptor endocytosis
and endosomal sorting. J. Cell Sci. 125, 265-275.
1414
RESEARCH ARTICLE Biology Open (2017) 6, 1404-1415 doi:10.1242/bio.027896
B
io
lo
g
y
O
p
en
 by guest on January 26, 2018http://bio.biologists.org/Downloaded from 
Hausott, B., Vallant, N., Hochfilzer, M., Mangger, S., Irschick, R., Haugsten,
E. M. and Klimaschewski, L. (2012). Leupeptin enhances cell surface
localization of fibroblast growth factor receptor 1 in adult sensory neurons by
increased recycling. Eur. J. Cell Biol. 91, 129-138.
Hershko, A. and Ciechanover, A. (1992). The ubiquitin system for protein
degradation. Annu. Rev. Biochem. 61, 761-807.
Howell, G. J., Herbert, S. P., Smith, J. M., Mittar, S., Ewan, L. C., Mohammed, M.,
Hunter, A. R., Simpson, N., Turner, A. J., Zachary, I. et al. (2004). Endothelial
cell confluence regulates Weibel-Palade body formation. Mol. Membr. Biol. 21,
413-421.
Jopling, H. M., Howell, G. J., Gamper, N. and Ponnambalam, S. (2011). The
VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma
membrane recycling. Biochem. Biophys. Res. Commun. 410, 170-176.
Jopling, H. M., Odell, A. F., Pellet-Many, C., Latham, A. M., Frankel, P.,
Sivaprasadarao, A.,Walker, J. H., Zachary, I. C. and Ponnambalam, S. (2014).
Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase
regulates endothelial function and blood vessel formation. Cells 3, 363-385.
Katz, M., Shtiegman, K., Tal-Or, P., Yakir, L., Mosesson, Y., Harari, D., Machluf,
Y., Asao, H., Jovin, T., Sugamura, K. et al. (2002). Ligand-independent
degradation of epidermal growth factor receptor involves receptor ubiquitylation
and hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by
Nedd4. Traffic 3, 740-751.
Koch, S. and Claesson-Welsh, L. (2012). Signal transduction by vascular
endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2,
a006502.
Koch, S., Tugues, S., Li, X., Gualandi, L. and Claesson-Welsh, L. (2011). Signal
transduction by vascular endothelial growth factor receptors. Biochem. J. 437,
169-183.
Lin, C.-C., Melo, F. A., Ghosh, R., Suen, K. M., Stagg, L. J., Kirkpatrick, J., Arold,
S. T., Ahmed, Z. and Ladbury, J. E. (2012). Inhibition of basal FGF receptor
signaling by dimeric Grb2. Cell 149, 1514-1524.
Maghsoudlou, A., Meyer, R. D., Rezazadeh, K., Arafa, E., Pudney, J.,
Hartsough, E. and Rahimi, N. (2016). Rnf121 inhibits angiogenic growth factor
signaling by restricting cell surface expression of vegfr-2. Traffic 17, 289-300.
Mittar, S., Ulyatt, C., Howell, G. J., Bruns, A. F., Zachary, I., Walker, J. H. and
Ponnambalam, S. (2009). VEGFR1 receptor tyrosine kinase localization to the
golgi apparatus is calcium-dependent. Exp. Cell Res. 315, 877-889.
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